These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38471994)

  • 41. Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With
    Johanns TM; Ferguson CJ; Grierson PM; Dahiya S; Ansstas G
    J Natl Compr Canc Netw; 2018 Jan; 16(1):4-10. PubMed ID: 29295876
    [No Abstract]   [Full Text] [Related]  

  • 42. Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient.
    Tamura A; Inaba Higashiyama R; Yoshida T; Satozono Y; Ohe Y
    Thorac Cancer; 2024 Jun; 15(18):1454-1456. PubMed ID: 38766698
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
    Marks AM; Bindra RS; DiLuna ML; Huttner A; Jairam V; Kahle KT; Kieran MW
    Pediatr Blood Cancer; 2018 May; 65(5):e26969. PubMed ID: 29380516
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
    Bourque MS; Salek M; Sabin ND; Canale M; Upadhyaya SA
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28814. PubMed ID: 33211390
    [No Abstract]   [Full Text] [Related]  

  • 45. Dabrafenib plus trametinib in patients with BRAF
    Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
    Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
    Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
    Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation.
    Dagogo-Jack I
    J Thorac Oncol; 2020 Oct; 15(10):e174-e176. PubMed ID: 32981611
    [No Abstract]   [Full Text] [Related]  

  • 48. BRAF-mutated, acral verrucous melanoma successfully treated by dabrafenib plus trametinib combination therapy.
    Kiyohara T; Nagano N; Miyamoto M; Shijimaya T; Nakamaru S; Makimura K; Tanimura H
    Clin Exp Dermatol; 2019 Dec; 44(8):945-946. PubMed ID: 30950075
    [No Abstract]   [Full Text] [Related]  

  • 49. Gastrointestinal perforation following dabrafenib and trametinib administration in non-small cell lung carcinoma with BRAF V600E mutation: a case report and literature review.
    Shimada Y; Sato Y; Tachikawa R; Hara S; Tomii K
    Invest New Drugs; 2021 Dec; 39(6):1702-1706. PubMed ID: 34023984
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance.
    Ernst T; Aebi S; Zander A; Zander T
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35396243
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful use of crushed formulation of dabrafenib and trametinib in a pediatric glioneural tumor.
    Mamdouhi T; Vagrecha A; Johnson AA; Levy CF; Atlas M; Krystal JI
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29187. PubMed ID: 34185373
    [No Abstract]   [Full Text] [Related]  

  • 52. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
    Algazi AP; Moon J; Lao CD; Chmielowski B; Kendra KL; Lewis KD; Gonzalez R; Kim K; Godwin JE; Curti BD; Latkovic-Taber M; Lomeli SH; Gufford BT; Scumpia PO; Lo RS; Othus M; Ribas A
    Cancer; 2024 May; 130(10):1784-1796. PubMed ID: 38261444
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition.
    Tsakonas G; Grozman V; Ekman S
    Clin Lung Cancer; 2020 Nov; 21(6):e544-e546. PubMed ID: 32522509
    [No Abstract]   [Full Text] [Related]  

  • 54. TTF-1 positive posterior pituitary tumor: Limitations of current treatment and potential new hope in BRAF V600E mutation variants.
    Dawoud FM; Naylor RM; Giannini C; Swanson AA; Meyer FB; Uhm JH
    Clin Neurol Neurosurg; 2020 Sep; 196():106059. PubMed ID: 32682222
    [No Abstract]   [Full Text] [Related]  

  • 55. Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL).
    González-Barrallo I; Castellón Rubio VE; Medina J; España S; Mujika K; Majem M; Aguado C; Cabrera Suárez MÁ; Palacio I; Osterloh L; Martínez-Fernández A; García-Castaño A
    Melanoma Res; 2022 Oct; 32(5):343-352. PubMed ID: 35762583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dabrafenib-trametinib is effective in paediatric high-grade glioma.
    Romero D
    Nat Rev Clin Oncol; 2023 Nov; 20(11):734. PubMed ID: 37726419
    [No Abstract]   [Full Text] [Related]  

  • 57. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
    Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC
    J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes in patients with
    Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto PA; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P
    Tumori; 2023 Dec; 109(6):537-545. PubMed ID: 37417313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
    Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.